PMID- 33591838
OWN - NLM
STAT- MEDLINE
DCOM- 20210805
LR  - 20210805
IS  - 2687-8941 (Electronic)
IS  - 2687-8941 (Linking)
VI  - 7
DP  - 2021 Feb
TI  - Clinical Characteristics and Histopathological Patterns of Hodgkin Lymphoma and 
      Treatment Outcomes at a Tertiary Cancer Center in Ethiopia.
PG  - 277-288
LID - 10.1200/GO.20.00391 [doi]
LID - GO.20.00391
AB  - PURPOSE: In developing countries, Hodgkin lymphoma (HL) affects the young 
      population. In Ethiopia, nearly 70% of the population are < 35 years of age. 
      Therefore, this study aimed to elucidate the age distribution, histopathologic 
      patterns, clinical characteristics and treatment outcomes of HL in Ethiopia. 
      MATERIALS AND METHODS: Data from clinical records of 133 consecutive patients 
      with HL between 2014 and 2019 were reviewed and collected. Formalin-fixed 
      paraffin-embedded tissue blocks of HL cases were collected and used for subtype 
      classification. RESULTS: A total of 68.4% (91) of the patients were male; 
      male-to-female ratio was 2.2:1. The median age was 22 years. The age distribution 
      was 57.1% (76), 30.8% (41), and 2.3% (3) for the age groups (10-29), (30-59), and 
      (60-69) years, respectively. Thirteen percent (12) were associated with HIV. The 
      majority of the cases, 50.4% (67), were of the mixed-cellularity (MCCHL) subtypes 
      and 30% (40) nodular-sclerosis (NSCCHL). Most HIV-associated cases (60%, 6) were 
      of the MCHL subtype. The 4-year overall survival (OS) was 83.1%. The 4-year OS of 
      early-stage patients was 100% and advanced-stage patients with low-risk 
      (International Prognostic Score [IPS] </= 2) and high-risk (IPS >/= 3) were 94.1% and 
      62.9%, respectively. All patients who received combined-therapy survived, whereas 
      those who received doxorubicin, bleomycin, vinblastine, and dacarbazine only 
      showed a 4-year OS rate of 77.9%. CONCLUSION: HL affects the youngest and most 
      productive population in Ethiopia. The treatment outcome is favorable in both 
      HIV-associated and non-HIV-associated HL. However, the study population was 
      likely a highly selected group as the majority of the Ethiopian population do not 
      have access to specialized care.
FAU - Adam, Makka
AU  - Adam M
AUID- ORCID: 0000-0001-9394-3726
AD  - Department of Microbial, Cellular and Molecular Biology, College of Natural 
      Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
AD  - Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
AD  - Department of Oncology, Faculty of Medicine, Lund University, Lund, Sweden.
AD  - Yirgalem Medical College, Yirgalem, Ethiopia.
FAU - Bekueretsion, Yonas
AU  - Bekueretsion Y
AD  - Department of Pathology, College of Health Sciences, Addis Ababa University, 
      Addis Ababa, Ethiopia.
FAU - Abubeker, Abdulaziz
AU  - Abubeker A
AD  - Department of Internal Medicine, College of Health Sciences, Addis Ababa 
      University, Addis Ababa, Ethiopia.
FAU - Tadesse, Fisihatsion
AU  - Tadesse F
AD  - Department of Internal Medicine, College of Health Sciences, Addis Ababa 
      University, Addis Ababa, Ethiopia.
FAU - Kwiecinska, Anna
AU  - Kwiecinska A
AD  - Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden.
FAU - Howe, Rawleigh
AU  - Howe R
AD  - Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
FAU - Petros, Beyene
AU  - Petros B
AD  - Department of Microbial, Cellular and Molecular Biology, College of Natural 
      Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
FAU - Jerkeman, Mats
AU  - Jerkeman M
AUID- ORCID: 0000-0003-4509-6707
AD  - Department of Oncology, Faculty of Medicine, Lund University, Lund, Sweden.
FAU - Gebremedhin, Amha
AU  - Gebremedhin A
AD  - Department of Internal Medicine, College of Health Sciences, Addis Ababa 
      University, Addis Ababa, Ethiopia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JCO Glob Oncol
JT  - JCO global oncology
JID - 101760170
RN  - 5V9KLZ54CY (Vinblastine)
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Ethiopia/epidemiology
MH  - Female
MH  - *Hodgkin Disease/drug therapy/epidemiology
MH  - Humans
MH  - Male
MH  - Treatment Outcome
MH  - Vinblastine/therapeutic use
MH  - Young Adult
PMC - PMC8081535
COIS- The following represents disclosure information provided by authors of this 
      manuscript. All relationships are considered compensated unless otherwise noted. 
      Relationships are self-held unless noted. I = Immediate Family Member, Inst = My 
      Institution. Relationships may not relate to the subject matter of this 
      manuscript. For more information about ASCO's conflict of interest policy, please 
      refer to www.asco.org/rwc or ascopubs.org/go/authors/author-center. Open Payments 
      is a public database containing information reported by companies about payments 
      made to US-licensed physicians (Open Payments). Mats Jerkeman Honoraria: 
      Janssen-Cilag, Celgene, Roche, Incyte Consulting or Advisory Role: Gilead 
      Sciences Research Funding: Janssen-Cilag, Celgene, AbbVie, Gilead Sciences No 
      other potential conflicts of interest were reported.
EDAT- 2021/02/17 06:00
MHDA- 2021/08/06 06:00
PMCR- 2021/02/16
CRDT- 2021/02/16 17:09
PHST- 2021/02/16 17:09 [entrez]
PHST- 2021/02/17 06:00 [pubmed]
PHST- 2021/08/06 06:00 [medline]
PHST- 2021/02/16 00:00 [pmc-release]
AID - GO.20.00391 [pii]
AID - 10.1200/GO.20.00391 [doi]
PST - ppublish
SO  - JCO Glob Oncol. 2021 Feb;7:277-288. doi: 10.1200/GO.20.00391.